Tested IV Hepabig in liver-transplant patients with hepatitis B
Part of Digestive system, Infections clinical trials.
This Phase 3 study checks whether an undiluted IV infusion of I.V.-Hepabig inj is safe and works to help prevent hepatitis B from coming back after a liver transplant. It is mainly for adults who had a hepatitis B–related liver transplant and already received Hepabig regularly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to under 65 when you sign consent
- You had a liver transplant for hepatitis B–related severe liver disease
- Your hepatitis B surface test (HBsAg) was positive before your transplant
- You’ve already received IV Hepabig more than 3 times using a 10,000 IU every 4 weeks schedule
- You cannot have had a severe allergic reaction (anaphylaxis) to Hepabig or its ingredients
- You must not have certain infections, pregnancy/breastfeeding, or major lab/health conditions that disqualify you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
This study tests an added hepatitis B immune medicine (HBV immunoglobulin) in people with chronic hepatitis B who have liver cancer and are planning surgery or a liver transplant. The goal is to see if giving this protection around the time of treatment can help prevent liver cancer from coming back or worsening.
This study tests a new injection called IB-001 in two groups: healthy people and people with chronic hepatitis B. The goal is to see if it's safe and how the body handles it at different doses. It might offer a new treatment option for hepatitis B in the future.
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.